Ich stimme der Verwendung von Cookies zu. Auch wenn ich diese Website weiter nutze, gilt dies als Zustimmung.

Bitte lesen und akzeptieren Sie die Datenschutzinformation und Cookie-Informationen, damit Sie unser Angebot weiter nutzen können. Natürlich können Sie diese Einwilligung jederzeit widerrufen.






21st Austria weekly - Valneva; AT&S (20/06/2022)

26.06.2022

Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022. As part of the Equity Subscription Agreement, Pfizer will invest €90.5 ($95) mn in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share, through a reserved capital increase to further support the strategic Lyme partnership between the two companies. The per share purchase price was determined based on the average closing price of the Company’s shares on Euronext Paris during the 10 trading days preceding the date of the Equity Subscription Agreement. The equity investment is due to close on June 22, 2022. Valneva is planning to use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program. In addition, Valneva and Pfizer updated the terms of their collaboration and license agreement which they announced on April 30, 2020. Valneva will now fund 40% of the remaining shared development costs compared to 30% in the initial agreement. Pfizer will pay Valneva tiered royalties ranging from 14% to 22%, compared to royalties starting at 19% in the initial agreement. In addition, the royalties will be complemented by up to $100 mn in milestones payable to Valneva based on cumulative sales. Other development and early commercialization milestones are unchanged, of which $168 million remain, including a $25 mn payment to Valneva upon Pfizer’s initiation of the Phase 3 study.
Valneva: weekly performance: 59.36%

AT&S: AT&S, manufacturer of high-end printed circuit boards and IC substrates, increased its guidance for the current financial year 2022/23. The company anticipates that revenue of roughly Euro 2.2 bn will be generated in the financial year 2022/23 (previously: approx. Euro 2 bn). The expected EBITDA margin adjusted for start-up costs will increase to 27 to 30% (previously: 23 to 26%). The assumptions regarding start-up costs (Euro 75 mn) and the investment volume (Euro 1,250 mn) remain unchanged. The outlook is based on the assumption that the global economy will not enter a recession, no direct negative financial effects of the geopolitical upheavals will result from the war in Ukraine and the Covid situation in China will not lead to any long-term production downtimes. 
AT&S: weekly performance: 8.01%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/06/2022)


Partners









latest 21st Austria

21st Austria weekly - Valneva; AT&S (20/06/2022)


26.06.2022, 2676 Zeichen



Valneva: Austrian/French vaccine company Valneva and Pfizer announced that they have entered into an Equity Subscription Agreement and have updated the terms of their Collaboration and License Agreement for Lyme disease vaccine candidate VLA15. As previously announced on April 26, 2022, Pfizer plans to initiate the Phase 3 study of VLA15 in the third quarter of 2022. As part of the Equity Subscription Agreement, Pfizer will invest €90.5 ($95) mn in Valneva, representing 8.1% of Valneva’s share capital at a price of €9.49 per share, through a reserved capital increase to further support the strategic Lyme partnership between the two companies. The per share purchase price was determined based on the average closing price of the Company’s shares on Euronext Paris during the 10 trading days preceding the date of the Equity Subscription Agreement. The equity investment is due to close on June 22, 2022. Valneva is planning to use the proceeds from Pfizer’s equity investment to support its Phase 3 development contribution to the Lyme disease program. In addition, Valneva and Pfizer updated the terms of their collaboration and license agreement which they announced on April 30, 2020. Valneva will now fund 40% of the remaining shared development costs compared to 30% in the initial agreement. Pfizer will pay Valneva tiered royalties ranging from 14% to 22%, compared to royalties starting at 19% in the initial agreement. In addition, the royalties will be complemented by up to $100 mn in milestones payable to Valneva based on cumulative sales. Other development and early commercialization milestones are unchanged, of which $168 million remain, including a $25 mn payment to Valneva upon Pfizer’s initiation of the Phase 3 study.
Valneva: weekly performance: 59.36%

AT&S: AT&S, manufacturer of high-end printed circuit boards and IC substrates, increased its guidance for the current financial year 2022/23. The company anticipates that revenue of roughly Euro 2.2 bn will be generated in the financial year 2022/23 (previously: approx. Euro 2 bn). The expected EBITDA margin adjusted for start-up costs will increase to 27 to 30% (previously: 23 to 26%). The assumptions regarding start-up costs (Euro 75 mn) and the investment volume (Euro 1,250 mn) remain unchanged. The outlook is based on the assumption that the global economy will not enter a recession, no direct negative financial effects of the geopolitical upheavals will result from the war in Ukraine and the Covid situation in China will not lead to any long-term production downtimes. 
AT&S: weekly performance: 8.01%

(From the 21st Austria weekly https://www.boerse-social.com/21staustria (20/06/2022)



BSN Podcasts
Christian Drastil: Wiener Börse Plausch

Wiener Börse Plausch S2/87: boersenbrief.at neu, Andritz-Legende setzt bei ams Osram Zeichen, Valneva und die Zecken




 

Bildnachweis

Aktien auf dem Radar:AT&S, S Immo, Pierer Mobility, Immofinanz, Porr, Kapsch TrafficCom, Lenzing, Marinomed Biotech, RBI, Telekom Austria, Flughafen Wien, Rosenbauer, Semperit, Wienerberger, Wolftank-Adisa, Wolford, Oberbank AG Stamm, Bawag, Polytec Group.


Random Partner

FACC
Die FACC ist führend in der Entwicklung und Produktion von Komponenten und Systemen aus Composite-Materialien. Die FACC Leichtbaulösungen sorgen in Verkehrs-, Fracht-, Businessflugzeugen und Hubschraubern für Sicherheit und Gewichtsersparnis, aber auch Schallreduktion. Zu den Kunden zählen u.a. wichtige Flugzeug- und Triebwerkshersteller.

>> Besuchen Sie 62 weitere Partner auf boerse-social.com/partner


Useletter

Die Useletter "Morning Xpresso" und "Evening Xtrakt" heben sich deutlich von den gängigen Newslettern ab. Beispiele ansehen bzw. kostenfrei anmelden. Wichtige Börse-Infos garantiert.

Newsletter abonnieren

Runplugged

Infos über neue Financial Literacy Audio Files für die Runplugged App
(kostenfrei downloaden über http://runplugged.com/spreadit)

per Newsletter erhalten